JMCP Article Discusses Payer Viewpoints Regarding RWE, Notes Widespread Use of Claims Data

August 6, 2021

An article published in the Journal Of Managed Care and Specialty Pharmacy discusses how real world evidence (RWE) can inform healthcare decision-making and bolster randomized controlled trials. Researchers conducted a survey of payers in the United States with the goal of understanding how payers view RWE in oncology research. The authors note that many nearly 80% of payers turned to claims data as a source of RWE. In-house studies were limited by several barriers, including a reported lack of experienced professionals.

“A national survey containing single-answer, multiple-answer, and free-response questions evaluated 4 key areas: (1) the value of RWE, (2) barriers to RWE, (3) sources of RWE, and (4) use of RWE in outcomes-based contracting…Payers valued RWE pre-launch to inform formulary and contracting decisions and desired real-world comparative effectiveness data post-launch to validate coverage decisions.” Read more here.

(Source: Brixner et al., JMCP, 8/2021)

Share This Story!